Ivabradine acutely improves cardiac Ca handling and function in a rat model of Duchenne muscular dystrophy
Physiological Reports · 2023
DOI: 10.14814/phy2.15664 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physiological Reports, 2023. Verfasst von Petra Lujza Szabo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Medical University of Vienna,…. Hauptthemen laut MEDLINE: Dystrophin, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund.
Abstract (Originalsprache)
The muscular dystrophies caused by dystrophin deficiency, the so‐called dystrophinopathies, are associated with impaired cardiac contractility and arrhythmias, which considerably contribute to disease morbidity and mortality. Impaired Ca handling in ventricular cardiomyocytes has been identified as a causative factor for complications in the dystrophic heart, and restoration of normal Ca handling in myocytes has emerged as a promising new therapeutic strategy. In the present study, we explored the hypothesis that ivabradine, a drug clinically approved for the treatment of heart failure and stable angina pectoris, improves Ca handling in dystrophic cardiomyocytes and thereby enhances contractile performance in the dystrophic heart. Therefore, ventricular cardiomyocytes were isolated from the hearts of adult dystrophin‐deficient DMD mdx rats, and the effects of acutely applied ivabradine on intracellular Ca transients were tested. In addition, the drug's acute impact on cardiac function in DMD mdx rats was assessed by transthoracic echocardiography. We found that administration of ivabradine to DMD mdx rats significantly improved cardiac function. Moreover, the amplitude of electrically induced intracellular Ca transients in ventricular cardiomyocytes isolated from DMD mdx rats was increased by the drug. We conclude that ivabradine enhances Ca release from the sarcoplasmic reticulum in dystrophic cardiomyocytes and thereby improves contractile performance in the dystrophic heart.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Medical University of Vienna, Vienna, 1090, Austria.
- Department of Neurophysiology and Neuropharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, 1090, Vienna, Austria.
ORCID-Profile: Attila Kiss, Karlheinz Hilber
Förderung
- Austrian Science Fund
Zitieren
APA
Szabo, P. L., Marksteiner, J., Ebner, J., Dostal, C., Podesser, B. K., Sauer, J., Kubista, H., Todt, H., Hackl, B., Koenig, X., Kiss, A., & Hilber, K. (2023). Ivabradine acutely improves cardiac Ca handling and function in a rat model of Duchenne muscular dystrophy. Physiological Reports. https://doi.org/10.14814/phy2.15664
Vancouver
Szabo PL, Marksteiner J, Ebner J, Dostal C, Podesser BK, Sauer J, et al. Ivabradine acutely improves cardiac Ca handling and function in a rat model of Duchenne muscular dystrophy. Physiological Reports. 2023. doi:10.14814/phy2.15664
BibTeX
@article{Szabo2023,
author = {Szabo, Petra Lujza and Marksteiner, Jessica and Ebner, Janine and Dostal, Christopher and Podesser, Bruno K and Sauer, Jakob and Kubista, Helmut and Todt, Hannes and Hackl, Benjamin and Koenig, Xaver and Kiss, Attila and Hilber, Karlheinz},
title = {Ivabradine acutely improves cardiac Ca handling and function in a rat model of Duchenne muscular dystrophy},
journal = {Physiological Reports},
year = {2023},
doi = {10.14814/phy2.15664}
}
EUVIMED